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We evaluated the risk of bladder cancer in a cohort of 79280 Swedish men hospitalised for benign prostatic hyperplasia (BPH),
identified in the Swedish Inpatient Register between 1964 and 1983 and followed until 1989 via multiple record linkages with
nationwide data on cancer registry, death and emigration. Standardised incidence ratios (SIRs), the ratios of the observed to the
expected numbers of incident bladder cancers, were used to calculate the risk associated with BPH. The expected number was
calculated by multiplying the number of person-years by the age-specific cancer incidence rates in Sweden for each 5-year age group
and calendar year of observation. Analyses were stratified by BPH treatment, latency, calendar year and presence of genitourinary
(GU) comorbid conditions. After excluding the first 3 years of follow-up after the index hospitalisation, we observed 506 incident
bladder cancer cases during follow-up in the cohort. No overall increased risk of bladder cancer was apparent in our main analysis
involving the entire BPH cohort. However, among BPH patients with transurethral resection of the prostate (TURP), there was an
increased risk in all follow-up periods; SIRs of bladder cancer during years 4–6 of follow-up was 1.22 (95% confidence
interval¼1.02–1.46), 1.32 for 7–9 years of follow-up, and 1.47 for 10–26 years of follow-up. SIRs of bladder cancer among TURP-
treated BPH patients were particularly elevated among those with comorbid conditions of the GU tract (e.g., stone, infection, etc.);
1.72, 1.74 and 2.01 for 4–6, 7–9, 10–26 years of follow-up, respectively, and also for those whose diagnoses occurred before 1975,
when TURP was more likely to be performed by a urologist than a general practitioner: 1.87, 1.90 and 1.74, respectively. These
findings suggest that BPH overall is not associated with bladder cancer risk. However, among men treated with TURP, particularly
those with other comorbid GU tract conditions, risk of bladder cancer was elevated.
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Benign prostatic hyperplasia (BPH) is a common condition
resulting in about 200000 transurethral resections of the prostate
(TURP) annually in the United States (Graves and Kozak, 1998).
Autopsy studies show anatomic or microscopic evidence of BPH in
approximately 20% of men aged 40–50 years, increasing to about
80% prevalence in men 70–80 years of age; however, only 25–50%
of men with microscopic BPH present with clinical manifestations
(Ziada et al, 1999).
BPH progression may cause lower urinary tract damage. Clinical
manifestation of obstruction from such damage includes increased
urinary symptoms, urodynamic evidence of reduced flow rate, and
increased post-void residual volume (Djavan et al, 2002). If left
untreated, a number of sequelae can occur, including acute urinary
retention, recurrent urinary tract infections, hydronephrosis and
even renal failure (Jacobsen et al, 2001).
Urinary retention resulting from untreated BPH may be a risk
factor for bladder cancer. A study of beagle dogs suggested that the
frequency of urination is inversely associated with the level of
potential carcinogens in the urothelium (Kadlubar et al, 1991).
In humans, a prospective study showed that a high fluid intake
may be associated with a decreased risk of bladder cancer in
men (Michaud et al, 1999). Thus, we hypothesised that urinary
retention or accumulation of residual urine caused or aggravated
by BPH increases contact time between carcinogens and the
urothelium, leading to increased bladder cancer risk. There have
been very few epidemiological studies of the association between
BPH and bladder cancer. Two case–control studies (Mommsen
and Sell, 1983; Nakata et al, 1995) reported that BPH may be
associated with increased bladder cancer risk (n¼165 and 303
cases, respectively). To further clarify the role of BPH in bladder
cancer prospectively, we examined the risk of this cancer in a large
national cohort of 87532 men hospitalised with BPH between 1964
and 1983 in Sweden. In stratified analyses, we separately evaluated
risk among BPH patients with recorded complications of the
outflow obstruction (stones, infections), which also are possible
risk factors for bladder cancer (Chow et al, 1997).
METHODS
BPH cohorts
All patients whose records in the Swedish Inpatient Register (IPR)
contained a discharge diagnosis code for BPH (International
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yClassification of Diseases (ICD)-7 610.10 or ICD-8 600.09) between
1964 and 1983, and whose national registration numbers were
complete and referable to a person alive and residing in Sweden at
the time of entry (first hospital diagnosis of BPH in the IPR), were
included in the cohort. A detailed description of this cohort, the
record-linkage data, and the methods of follow-up used in the
current study have been presented previously (Nyren et al, 1995;
Chokkalingam et al, 2003). Of 87532 patients with a discharge
diagnosis of BPH, 79280 were included in the study after excluding
patients with any cancer diagnosed before the entry date (n¼8252,
about 20% of these were bladder cancer). Based on the type of BPH
treatment received at entry into the cohort (index BPH diagnosis),
the 79280 patients were categorised into four groups: 21995
(27.7%) had no surgery, 37410 (47.2%) had TURP, 19035 (24.0%)
had transvesical adenomectomy (TA, open surgery for removal of
the entire inner core of the prostate), and 840 (1.0%) had both
TURP and TA. Because of small numbers, no subgroup analyses
were conducted among the 840 patients who received both TURP
and TA; they were included only in analyses of all BPH patients.
Comorbid conditions of genitourinary tract
Up to six diagnoses can be entered in the IPR per hospital
admission. To evaluate the joint effect of BPH and comorbid
conditions of the genitourinary (GU) tract on bladder cancer
development, we examined the following diagnoses that were
identified at the initial BPH visit as GU comorbidities: ICD-7 codes
590.10–609.99 and ICD-8 codes 580.99–607.98. The most common
comorbid GU conditions (45%) were (in descending order):
nonspecific urinary tract infections (n¼2499, 14.4%), urethral
stricture (n¼1514, 8.7%), bladder stone (n¼1258, 7.2%), and
ureter stone (n¼1068, n¼6.2%).
Follow-up: bladder cancer ascertainment
Incident bladder cancer cases diagnosed between 1964 and 1989
were identified by record linkage of the IPR data to the Swedish
Cancer Registry based on national registration numbers.
Statistical analysis
Standardised incidence rates (SIR) were calculated as the ratio of
the observed to the expected numbers of events, computed by
multiplying the number of person-years at risk by age-specific
cancer incidence rates in Sweden for each 5-year age group and
calendar year of observation. Person-years at risk were calculated
from the admission date for the hospital visit during which BPH
was first recorded to the date of first cancer (any, including
bladder cancer), emigration, death or end of the observation
period (December 31, 1989), whichever occurred first after BPH
diagnosis. However, because presence of an undiagnosed cancer is
likely to increase the probability of hospital admission for another
diagnosis, such as BPH, and as the screening involved in the work-
up of patients with BPH may also increase the detection of cancer
during the first few years of follow-up, we reframed from
interpreted person-time and cancer occurrences in the first 3
years following the index BPH hospitalisation. The 95% confidence
interval (CI) of the SIR was calculated based on the assumption
that the observed number follows a Poisson distribution (Bailar
and Ederer, 1964). We computed P-values from a chi-statistic to
test for trends in SIRs with increasing years of follow-up, and
P-values from w
2 tests of homogeneity between various patient
subgroups (Tables 1–3). None of these P-values were statistically
significant (Po0.05) (Breslow and Day, 1987).
RESULTS
During the 26-year follow-up period (569370 persons-years), 910
incident primary bladder cancer cases were identified (Table 1).
Excluding the first 3 years of follow-up, 506 bladder cancer cases
remained for further analysis. There was no significant increased
risk of bladder cancer in BPH patients overall. However,
nonsignificant, gradually increasing SIRs above 1 were observed
for the follow-up periods 4–6, 7–9 and 10–26. In addition, BPH
patients who underwent TURP had a significantly increased risk
of bladder cancer in all follow-up periods; SIRs of bladder cancer
for 4–6 years of follow-up was 1.22 (95% CI¼1.02–1.46), 1.32
(95% CI¼1.06–1.62) for 7–9 years of follow-up and 1.47 (95%
CI¼1.14–1.87) for 10–26 years of follow-up (P for trend¼0.23).
BPH patients without surgical treatment showed no excess risk,
whereas those with transvesicular adenomectomy showed a
nonsignificant decreased risk. The test for homogeneity among
these cohorts was not statistically significant (P¼0.66).
Table 2 shows risk in relation to BPH by presence of comorbid
conditions of the GU tract (e.g., stones, infections, etc.) at the time
of BPH diagnosis, as listed in the IPR. The SIR of bladder cancer
after 10 or more years of follow-up was elevated in all BPH patients
Table 1 Standardised incidence ratio (SIR)
a and 95% confidence intervals (CIs) for bladder cancer among patients diagnosed with benign prostatic
hyperplasia in Sweden, 1964–1983
All BPH patients No surgery TURP TA
Follow-up years Obs Exp SIR (95% CI) Obs Exp SIR (95% CI) Obs Exp SIR (95% CI) Obs Exp SIR (95% CI)
(n¼79280) (n¼21995) (n¼37410) (n¼19035)
1 215 70.7 3.04 (2.65–3.47) 84 19.0 4.42 (3.53–5.47) 94 34.2 2.75 (2.22– –3.37) 33 16.8 1.96 (1.35–2.75)
2 105 71.0 1.48 (1.21–1.79) 26 16.9 1.54 (1.01–2.26) 49 35.6 1.38 (1.02–1.82) 26 17.8 1.46 (0.95–2.14)
3 84 69.0 1.22 (0.97–1.51) 15 14.9 1.01 (0.56–1.66) 49 35.5 1.38 (1.02–1.83) 20 17.9 1.12 (0.68–1.73)
4 70 66.8 1.05 (0.82–1.32) 14 13.2 1.06 (0.58–1.78) 38 35.0 1.09 (0.77–1.49) 17 17.8 0.95 (0.56–1.53)
5–6 130 125.9 1.03 (0.86–1.23) 11 22.5 0.49 (0.24–0.87) 87 67.1 1.30 (1.04–1.60) 25 34.8 0.72 (0.47–1.06)
7–8 120 101.3 1.18 (0.98–1.42) 14 17.0 0.83 (0.45–1.39) 72 51.7 1.39 (1.09–1.75) 30 31.2 0.96 (0.65–1.37)
9–10 70 68.6 1.02 (0.80–1.29) 16 12.1 1.33 (0.76–2.16) 37 30.2 1.22 (0.86–1.69) 16 25.1 0.64 (0.36–1.04)
11–15 95 81.5 1.17 (0.94–1.42) 19 15.9 1.20 (0.72–1.87) 42 27.3 1.54 (1.11–2.08) 27 36.4 0.74 (0.49–1.08)
16–26 21 21.8 0.96 (0.60–1.47) 3 5.3 0.56 (0.11–1.64) 6 4.7 1.29 (0.47–2.80) 12 11.0 1.09 (0.56–1.90)
(n¼61312) (n¼12502) (n¼31478) (n¼16,565)
4–6 200 192.7 1.04 (0.90–1.19) 25 35.7 0.70 (0.45–1.03) 125 102.1 1.22 (1.02–1.46) 42 52.6 0.80 (0.58–1.08)
7–9 155 139.1 1.11 (0.95–1.30) 24 23.5 1.02 (0.65–1.52) 91 69.0 1.32 (1.06–1.62) 35 44.6 0.79 (0.55–1.09)
10–26 151 134.1 1.13 (0.95–1.32) 28 26.7 1.05 (0.70–1.52) 66 44.9 1.47 (1.14–1.87) 50 59.2 0.85 (0.63–1.11)
Abbreviations: BPH¼benign prostatic hyperplasia; TURP¼transurethral resection of the prostate; TA¼transvesicular adenomectomy.
aAdjusted for age (in 5-year intervals)
and calendar time period (in 5-year intervals).
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In particular, risk was elevated in TURP-treated BPH patients with
comorbid conditions of the GU tract, with significant SIRs of
1.72, 1.74 and 2.01, for 4–6, 7–9 and 10–26 years of follow-up,
respectively (Table 2). However, the increasing trend in risk over
follow-up time was not significant. Urethral stricture was the only
specific comorbidity associated with a significantly increased risk,
but this observation was based on only 18 bladder cancer cases.
All other uncommon (prevalence o5%) GU comorbid conditions
(e.g., pyelonephritis, pyelocystitis, renal cyst, cystitis, etc.) had
nonsignificantly increased risk of bladder cancer (data not shown).
Table 3 shows risk in each treatment subgroup by calendar year
of BPH diagnosis (o1975, 1975þ), as TURP gradually replaced
TA in Sweden during the 1970s and 1980s and was generally
performed by urologists. We found that, although there was no
significant association of BPH with bladder cancer overall by
calendar year, the risk of bladder cancer was significantly elevated
only in TURP-treated BPH cases diagnosed before 1975. The test
for homogeneity of SIRs between the two time periods was not
statistically significant (P¼0.67).
DISCUSSION
In this large cohort study in Sweden, we found no significant
overall excess risk of bladder cancer among all BPH patients. After
stratifying by type of BPH treatment (TURP, TA, no surgery), BPH
patients treated with TURP, a less invasive surgical intervention,
had a significantly increased risk of bladder cancer compared with
the general Swedish population. However, there was no significant
increased risk among BPH patients without surgery and a
nonsignificantly decreased risk among BPH patients with TA, an
open surgical procedure.
One of the reasons we set out to examine the risk of bladder
cancer following diagnosis of BPH was the potential that through
increased urinary retention and post-void residual urine, urinary
symptoms often associated with BPH, the urothelium of the
bladder may have increased contact and exposure to potential
carcinogens. However, the absence of a significant association of
bladder cancer risk with total BPH in this study does not support
this hypothesis. Nevertheless, increased risks were observed for
BPH patients treated with TURP and with GU comorbid conditions
even after 10 years of follow-up, suggesting such symptoms may
contribute, at least partly, to an increased risk of bladder cancer in
these patients. Indeed, several GU conditions, such as urinary tract
infections and stones, have been associated with an increased risk
(Nakata et al, 1995).
Other possible reasons for the elevation in the TURP-treated
BPH patients include surveillance or treatment selection bias.
The probability of surveillance bias is likely to be small, as we
focused on bladder cancer cases diagnosed at least 4 years after
BPH diagnosis. Differences in risk across various treatment sub-
cohorts suggest that factors related to selection of treatment may
have influenced, in part, subsequent risk of bladder cancer among
Table 2 Standardised incidence ratio (SIR)
a and 95% confidence intervals (95% CI) for bladder cancer among patients diagnosed with benign prostatic
hyperplasia in Sweden, 1964–1983 by comorbidity
b of genitourinary tract conditions
All BPH patients BPH without surgery BPH with TURP BPH with TA
GU Comorbidity Follow-up Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI
No (n¼50571) (n¼9803) (n¼26072) (n¼14211)
4–6 158 160.1 0.99 (0.84–1.15) 18 28.2 0.64 (0.38–1.01) 96 85.2 1.13 (0.91–1.38) 36 45.2 0.80 (0.56–1.10)
7–9 123 115.1 1.07 (0.89–1.27) 17 18.5 0.92 (0.53–1.47) 70 57.0 1.23 (0.96–1.55) 31 38.4 0.81 (0.55–1.15)
10–26 115 108.7 1.06 (0.87–1.27) 22 21.1 1.04 (0.65–1.58) 46 35.0 1.32 (0.96–1.76) 42 50.8 0.83 (0.60–1.12)
Yes (n¼10741) (n¼2699) (n¼5406) (n¼2354)
4–6 42 32.6 1.29 (0.93–1.74) 7 7.5 0.93 (0.37–1.91) 29 16.8 1.72 (1.15–2.47) 6 7.4 0.81 (0.30–1.77)
7–9 32 24.0 1.33 (0.91–1.88) 7 5.0 1.41 (0.56–2.90) 21 12.1 1.74 (1.08–2.66) 4 6.2 0.64 (0.17–1.65)
10–26 36 25.4 1.42 (0.99–1.96) 6 5.6 1.07 (0.39–2.32) 20 10.0 2.01 (1.23–3.10) 8 8.4 0.95 (0.41–1.88)
P
c 0.68 0.77 0.50 0.74
Abbreviations: BPH¼benign prostatic hyperplasia; TURP¼transurethral resection of the prostate; TA¼transvesicular adenomectomy.
aAdjusted for age.
bComorbid conditions
include nonspecific urinary tract infections, urethral stricture, bladder stone, ureter stone.
cP-value for heterogeneity between SIR for no comorbidity vs with comorbidity within
each subcohort.
Table 3 Standardised incidence ratio (SIR)
a and 95% confidence intervals (95% CI) for bladder cancer among patients diagnosed with benign prostatic
hyperplasia in Sweden, 1964-1983 by year of BPH diagnosis
All BPH patients BPH without surgery BPH with TURP BPH with TA
Follow-up Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI
o1975 (n¼16492) (n¼5249) (n¼3630) (n¼7278)
4–6 51 44.4 1.15 (0.86–1.51) 9 13.3 0.68 (0.31–1.28) 18 9.6 1.87 (1.11–2.95) 20 20.5 0.97 (0.59–1.50)
7–9 43 38.7 1.11 (0.80–1.50) 11 10.0 1.10 (0.55–1.96) 17 9.0 1.90 (1.10–3.04) 13 18.8 0.69 (0.37–1.18)
10–26 93 81.2 1.14 (0.92–1.40) 20 19.1 1.05 (0.64–1.62) 33 19.0 1.74 (1.19–2.44) 35 40.6 0.86 (0.60–1.20)
1975–1983 (n¼44820) (n¼7253) (n¼27848) (n¼9287)
4–6 149 148.3 1.00 (0.85–1.18) 16 22.4 0.71 (0.41–1.16) 107 92.4 1.16 (0.95–1.40) 22 32.0 0.69 (0.43–1.04)
7–9 112 100.4 1.12 (0.92–1.34) 13 13.5 0.96 (0.51–1.65) 74 60.1 1.23 (0.97–1.55) 22 25.7 0.85 (0.54–1.29)
10–26 58 52.9 1.10 (0.83–1.42) 8 7.6 1.05 (0.45–2.08) 33 25.9 1.27 (0.88–1.79) 15 18.5 0.81 (0.45–1.34)
P
b 0.70 0.27 0.49 0.94
P
c 0.67
Abbreviations: BPH¼benign prostatic hyperplasia; TURP¼transurethral resection of the prostate; TA¼transvesicular adenomectomy.
aAdjusted for age.
bP-value for
homogeneity test between calendar time periods.
cP-value for overall homogeneity test between two calendar time periods and three treatment methods (three subcohorts).
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influencing selection of BPH treatment. In this study, the TA
subcohort is generally healthiest, followed by the TURP group and
then the non-surgical group, as evidenced by lower mortality rates
from non-GU comorbidities, including cardiovascular disease,
diabetes mellitus and respiratory disease (Blomqvist et al, 1997). In
addition, the index hospital discharge diagnosis of BPH was the
primary diagnosis for only 53% of non-surgical patients, compared
with 89 and 88% of TA and TURP participants, respectively
(Blomqvist et al, 1997), suggesting that those undergoing surgery
were less likely to have other health concerns.
On the other hand, when the BPH diagnosis was only secondary,
misclassification of BPH is likely. Compared with the primary
diagnoses, the secondary BPH diagnoses were more often made by
doctors who were not specialists in urology. The average severity
of the clinical manifestation may also have been less compared
with patients who had BPH as the primary diagnosis. If there is a
true relationship between BPH and bladder cancer, possible
misclassification of the condition in some patients and a generally
less severe disease may have contributed to the absence of any
observable association in non-operated BPH patients.
Among BPH patients undergoing TURP, we observed an
increased risk among those first hospitalised for BPH before
1975, but not for those first hospitalised in the later time period,
suggesting that earlier index years are associated with greater
bladder cancer risk. This finding could result from long latency of
bladder cancer development, which is supported by the finding
that increased risk of bladder cancer was more pronounced in BPH
cases with follow-up of greater than 10 years. Alternatively, it could
result from changes in medical practice, such as differences in the
recommendations for TURP over time (Blomqvist et al, 1997). In
Sweden, the use of TURP grew over the study period (B20% of
BPH patients for pre-1975, B60% for post-1975).
Another possible explanation for the observed excess bladder
cancer risk among TURP-treated BPH patients is the TURP
procedure itself. Although TURP is regarded as the gold standard
for the management of BPH, follow-up studies reveal failures and
complications in 1–18% of patients (Mebust et al, 1989; Faul,
1993; Blomqvist et al, 1997; Borth et al, 2001). Compared with
TA, TURP treatment may not completely excise the enlarged
prostate, and it is possible that incomplete BPH treatment may
increase the risk of BPH-related adverse effects, such as urinary
retention, post-void residual urine, and other urinary symptoms,
which may, in turn, increase the risk of bladder cancer. A
complicated postoperative course, on the other hand, may give
scope of increased surveillance with entailing detection bias.
Further studies are needed to clarify the nature of the observed
association.
This study has several strengths. First, unlike previous studies of
BPH, which were of a case-control design, the prospective nature
of this study rules out recall bias. Second, cancer case ascertain-
ment was conducted by using the comprehensive national health
record system in Sweden, which was virtually complete by the end
of follow-up (Mattsson and Wallgren, 1984). Third, the popula-
tion-based nature of the IPR ensures maximal representation
of the study base. Fourth, we were able to utilise both surgical
and diagnostic data collected in the IPR, including other comorbid
conditions of the GU tract, to investigate reasons for the observed
results. Finally, the large sample size and long duration of follow-
up in this study provide good statistical power with which to
observe an association between BPH and bladder cancer, if one
exists.
There are a few limitations in our study. Potential confounders
were incompletely adjusted for in the study, because we do not
have information on some known bladder cancer risk factors (e.g.,
smoking, occupation). In addition, multiple comparisons and
subgroup analysis could have led to chance findings. Also, it
should be noted that we used first date of hospitalisation for BPH
as a proxy for date of BPH diagnosis, although it is clear that
the diagnosis and onset of BPH can take place before the first
hospitalisation for BPH. Because of the nature of in-patient data,
only BPH patients who needed treatment were included in this
nation-wide database. We were not able to include less severe
BPH patients, thereby limiting our generalisability. Furthermore,
because we identified our subcohorts based on their BPH
treatment noted on the first hospitalisation for BPH (entry
into the cohort), a small amount of person time attributed to the
non-surgical subcohorts should have been distributed to the
surgical subcohorts. The reason for our analytical technique was to
avoid the forward bias (Lubin and Gail, 1984). However, as only
252 of the 12502 BPH patients during the 26-year follow-up belong
to this group, the extent of misclassification of person-time is
minimal.
In conclusion, this large cohort study indicated that BPH did
not influence subsequent risk of bladder cancer overall. However,
among men treated with TURP, a less invasive surgical interven-
tion, risk of bladder cancer was elevated, particularly among men
with other comorbid GU tract conditions.
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